litlas
Log inCreate account

Michael Millward

Active 1993–2025

115
Papers
18,397
Citations
63
h-index
109
i10-index

Citations

Citations per year for Michael Millward1994: 2 citations1995: 2 citations1996: 2 citations1997: 3 citations1998: 6 citations1999: 9 citations2000: 10 citations2001: 14 citations2002: 16 citations2003: 10 citations2004: 14 citations2005: 30 citations2006: 32 citations2007: 39 citations2008: 50 citations2009: 62 citations2010: 68 citations2011: 62 citations2012: 83 citations2013: 210 citations2014: 226 citations2015: 296 citations2016: 250 citations2017: 299 citations2018: 250 citations2019: 688 citations2020: 751 citations2021: 730 citations2022: 649 citations2023: 491 citations2024: 784 citations2025: 306 citations2026: 11 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,143 citing papers, 24.4% of this breakdownChina: 857 citing papers, 9.8% of this breakdownItaly: 585 citing papers, 6.7% of this breakdownAustralia: 555 citing papers, 6.3% of this breakdownGermany: 498 citing papers, 5.7% of this breakdownUnited Kingdom: 480 citing papers, 5.5% of this breakdownFrance: 407 citing papers, 4.7% of this breakdownNetherlands: 328 citing papers, 3.7% of this breakdownSpain: 290 citing papers, 3.3% of this breakdownCanada: 248 citing papers, 2.8% of this breakdownSwitzerland: 244 citing papers, 2.8% of this breakdownJapan: 203 citing papers, 2.3% of this breakdown
0%24.4%Other 22%

Institutions

Fields

  • Medicine52.1%
  • Biochemistry, Genetics and Molecular Biology38.1%
  • Immunology and Microbiology5.4%
  • Computer Science0.7%
  • Engineering0.7%
  • Materials Science0.6%
  • Other2.4%

Topics

  • Melanoma and MAPK Pathways9.8%
  • Cancer Immunotherapy and Biomarkers7.6%
  • Cutaneous Melanoma Detection and Management4.9%
  • Immunotherapy and Immune Responses4%
  • Lung Cancer Treatments and Mutations4%
  • CAR-T cell therapy research3.7%
  • Other66%

Coauthors

All papers

Open in search
  1. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    Authors: Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, E. Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean‐Jacques Grob, Vanna Chiarion‐Sileni, Célèste Lebbé, Mario Mandalà, Michael Millward, Ana Arance, Igor Bondarenko, John B.A.G. Haanen, Johan Hansson, Jochen Utikal, Virginia Ferraresi, Н. В. Коваленко, Peter Mohr, Volodymyr Probachai, Dirk Schadendorf, Paul Nathan, Caroline Robert, Antoni Ribas, Douglas J. DeMarini, Jhangir G Irani, Michelle Casey, Danièle Ouellet, Anne‐Marie Martin, Ngocdiep T. Le, Kiran Patel, Keith T. Flaherty - New England Journal of Medicine 2014 cited by 1,871

  2. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

    Authors: Axel Hauschild, Jean‐Jacques Grob, Lev Demidov, Thomas Jouary, Ralf Gutzmer, Michael Millward, Piotr Rutkowski, Christian U. Blank, Wilson H. Miller, Eckhart Kaempgen, Salvador Martín‐Algarra, Bogusława Karaszewska, Cornelia Mauch, Vanna Chiarion‐Sileni, Anne-Marie Martin, S. Swann, Patricia Haney, Beloo Mirakhur, Mary Guckert, Vicki Goodman, Paul B. Chapman - The Lancet 2012 cited by 2,960

  3. Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

    Authors: Paolo A. Ascierto, Michele Del Vecchio, Mario Mandalà, Helen Gogas, Ana Arance, Stéphane Dalle, C. Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Marcus O. Butler, Michele Maio, Mark R. Middleton, Luis de la Cruz‐Merino, Petr Arenberger, Victoria Atkinson, Andrew Hill, Leslie A. Fecher, Michael Millward, Nikhil I. Khushalani, Paola Queirolo, Maurice Lobo, Veerle de Pril, John T. Loffredo, James Larkin, Jeffrey S. Weber - The Lancet Oncology 2020 cited by 525

  4. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

    Authors: Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, E. Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean‐Jacques Grob, Vanna Chiarion‐Sileni, Célèste Lebbé, Mario Mandalà, Michael Millward, Ana Arance, Igor Bondarenko, John B.A.G. Haanen, Johan Hansson, Jochen Utikal, Virginia Ferraresi, Н. В. Коваленко, Peter Mohr, Volodymr Probachai, Dirk Schadendorf, Paul Nathan, Caroline Robert, Antoni Ribas, Douglas J. DeMarini, Jhangir G Irani, S. Swann, Jeffrey J. Legos, Fan Jin, Bijoyesh Mookerjee, Keith T. Flaherty - The Lancet 2015 cited by 1,386

  5. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

    Authors: James Larkin, Michele Del Vecchio, Mario Mandalà, Helen Gogas, Ana Arance, Stéphane Dalle, Charles Lance Cowey, Michael Schenker, Jean‐Jacques Grob, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Marcus O. Butler, Anna Maria Di Giacomo, Mark R. Middleton, Jose Lutzky, Luis de la Cruz‐Merino, Petr Arenberger, Victoria Atkinson, Andrew G. Hill, Leslie A. Fecher, Michael Millward, Paul Nathan, Nikhil I. Khushalani, Paola Queirolo, Corey Ritchings, Maurice Lobo, Margarita Askelson, Hao Tang, Sonia Dolfi, Paolo A. Ascierto, Jeffrey S. Weber - Clinical Cancer Research 2023 cited by 180

  6. Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

    Authors: Mengzhao Wang, James Chih-Hsin Yang, Paul L. Mitchell, Jian Fang, D. Ross Camidge, Weiqi Nian, Chao-Hua Chiu, Jianying Zhou, Yanqiu Zhao, Wu-Chou Su, Tsung-Ying Yang, Viola W. Zhu, Michael Millward, Yun Fan, Wen-Tsung Huang, Ying Cheng, Liyan Jiang, Daniel Brungs, Lyudmila Bazhenova, Chee Khoon Lee, Bo Gao, Yan Xu, Wei-Hsun Hsu, Li Zheng, Pasi A. Jänne - Cancer Discovery 2022 cited by 119

  7. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

    Authors: Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock, Kevin B. Kim, Tobias Arkenau, Michael P. Brown, Omid Hamid, Jeffrey R. Infante, Michael Millward, Anna C. Pavlick, Steven O’Day, Samuel C. Blackman, C. Martin Curtis, Peter F. Lebowitz, Bo Ma, Danièle Ouellet, Richard Kefford - The Lancet 2012 cited by 933

  8. Abstract CT006: First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations

    Authors: Timothy A. Yap, David J. Kwiatkowski, Jayesh Desai, Ibiayi Dagogo‐Jack, Michael Millward, Hedy L. Kindler, Anthony W. Tolcher, Sophia Frentzas, Archie Thurston, Len Post, F Andrew Dorr - Cancer Research 2023 cited by 64

  9. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment

    Authors: Rachael M. Zemek, Emma de Jong, Wee Loong Chin, Iona S. Schuster, Vanessa S. Fear, Thomas Casey, Cath Forbes, Sarah Dart, Connull Leslie, Ayham Zaitouny, Michael Small, Louis Boon, Alistair R. R. Forrest, Daithi O. Muiri, Mariapia A. Degli‐Esposti, Michael Millward, Anna K. Nowak, Timo Lassmann, Anthony Bosco, Richard Lake, W. Joost Lesterhuis - Science Translational Medicine 2019 cited by 216

  10. Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

    Authors: Jayesh Desai, Hui Gan, Catherine Barrow, Michael B. Jameson, Victoria Atkinson, Andrew Haydon, Michael Millward, Stephen Begbie, Michael P. Brown, Ben Markman, W. K. Patterson, Andrew Hill, Lisa G. Horvath, Adnan Nagrial, Gary Richardson, Christopher Jackson, Michael Friedländer, Phillip Parente, Ben Tran, Lai Wang, Yunxin Chen, Zhiyu Tang, Wendy Huang, John Wu, Dewan Zeng, Lusong Luo, Benjamin Solomon - Journal of Clinical Oncology 2020 cited by 109

  11. Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity

    Authors: W. Joost Lesterhuis, Anthony Bosco, Michael Millward, Michael Small, Anna K. Nowak, Richard Lake - Nature Reviews Drug Discovery 2017 cited by 258

  12. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆

    Authors: C. Owen, Alexander N. Shoushtari, D Chauhan, David Palmieri, Belinda Lee, Maartje W. Rohaan, Joanna Mangana, Victoria Atkinson, Farzana Y. Zaman, Arissa Young, Christoph Höeller, Peter Hersey, R. Dummer, Muhammad A. Khattak, Michael Millward, Sapna P. Patel, Andrew Haydon, Douglas B. Johnson, Serigne Lo, Christian U. Blank, Shahneen Sandhu, Matteo S. Carlino, James Larkin, Alexander M. Menzies, Georgina V. Long - Annals of Oncology 2020 cited by 110

  13. A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer

    Authors: Ryan J. Sullivan, Antoine Hollebecque, Keith T. Flaherty, Geoffrey I. Shapiro, Jordi Rodon Ahnert, Michael Millward, Wei Zhang, Ling Gao, Amanda K. Sykes, Melinda D. Willard, Danni Yu, Andrew E. Schade, KrisAnne Crowe, Daniel L. Flynn, Michael D. Kaufman, James R. Henry, Sheng-Bin Peng, Karim A. Benhadji, Ilaria Conti, Michael S. Gordon, Ramón V. Tiu, David S. Hong - Molecular Cancer Therapeutics 2019 cited by 87

  14. A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors

    Authors: Sophia Frentzas, Hui Gan, Rasha Cosman, Jermaine Coward, Ben Tran, Michael Millward, Yiting Zhou, Wenjing Wang, Dennis Xia, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Jayesh Desai - Cell Reports Medicine 2023 cited by 39

  15. Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors

    Authors: Jenny Lee, Alexander M. Menzies, Matteo S. Carlino, Ashleigh C. McEvoy, Shahneen Sandhu, Alison M. Weppler, Russell J. Diefenbach, Sarah‐Jane Dawson, Richard Kefford, Michael Millward, Zeyad Al‐Ogaili, Thien Tra, Elin S. Gray, Stephen Q. Wong, Richard A. Scolyer, Georgina V. Long, Helen Rizos - Clinical Cancer Research 2020 cited by 82

  16. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors

    Authors: Jean‐Charles Soria, Hui Gan, Sarah P. Blagden, Ruth Plummer, H.T. Arkenau, Marie Ranson, T.R. Jeffry Evans, Gérard Zalcman, Rastislav Bahleda, Antoine Hollebecque, Charlotte Lemech, Emma Dean, Jennifer Brown, D. Gibson, Vijay Peddareddigari, Sonya R Murray, Noelia Nebot, Jolly Mazumdar, Leslie Swartz, K R Auger, Ronald A. Fleming, R. Singh, Michael Millward - Annals of Oncology 2016 cited by 145

  17. Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice

    Authors: Rachael M. Zemek, Wee Loong Chin, Vanessa S. Fear, Ben Wylie, Thomas Casey, Cath Forbes, Caitlin M. Tilsed, Louis Boon, Belinda B. Guo, Anthony Bosco, Alistair R. R. Forrest, Michael Millward, Anna K. Nowak, Richard Lake, Timo Lassmann, W. Joost Lesterhuis - Nature Communications 2022 cited by 47

  18. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma

    Authors: Elin S. Gray, Helen Rizos, Anna Reid, Suzanah C. Boyd, Michelle R. Pereira, Johnny Lo, Varsha Tembe, James Freeman, Jenny Lee, Richard A. Scolyer, Kelvin Shenq Woei Siew, Chris Lomma, Adam Cooper, Muhammad A. Khattak, Tarek Meniawy, Georgina V. Long, Matteo S. Carlino, Michael Millward, Mel Ziman - Oncotarget 2015 cited by 329

  19. Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy

    Authors: Gabriela Marsavela, Jenny Lee, Leslie Calapre, Stephen Q. Wong, Michelle R. Pereira, Ashleigh C. McEvoy, Anna Reid, Cleo Robinson, Lydia Warburton, Afaf Abed, Muhammad A. Khattak, Tarek Meniawy, Sarah‐Jane Dawson, Shahneen Sandhu, Matteo S. Carlino, Alexander M. Menzies, Richard A. Scolyer, Georgina V. Long, Benhur Amanuel, Michael Millward, Mel Ziman, Helen Rizos, Elin S. Gray - Clinical Cancer Research 2020 cited by 63

  20. ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study

    Authors: Charlotte Lemech, Ganessan Kichenadasse, Jens‐Peter Marschner, Konstantinos Alevizopoulos, Marit Otterlei, Michael Millward - Oncogene 2022 cited by 38

  21. Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors.

    Authors: Mitesh J. Borad, Alison M. Schram, Richard D. Kim, Suneel D. Kamath, Vaibhav Sahai, Efrat Dotan, Robin Kate Kelley, Mariano Ponz‐Sarvisé, Do‐Youn Oh, Jeffrey Yachnin, Vaia Florou, Philippe A. Cassier, Joon Oh Park, Chih‐Yi Liao, Michael Millward, Florence Ramirez, Fabien Ricard, Antoine Hollebecque, Vivek Subbiah, Lipika Goyal - Journal of Clinical Oncology 2023 cited by 37

  22. Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy

    Authors: Afaf Abed, Ngie Law, Leslie Calapre, Johnny Lo, Vikas Bhat, Samantha Bowyer, Michael Millward, Elin S. Gray - European Journal of Cancer 2022 cited by 32

  23. Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

    Authors: Kevin B. Kim, Richard Kefford, Anna C. Pavlick, Jeffrey R. Infante, Antoni Ribas, Jeffrey A. Sosman, Leslie A. Fecher, Michael Millward, Grant A. McArthur, Patrick Hwu, René González, Patrick A. Ott, Georgina V. Long, Olivia Gardner, Danièle Ouellet, Yanmei Xu, Douglas J. DeMarini, Ngocdiep T. Le, Kiran Patel, Karl D. Lewis - Journal of Clinical Oncology 2012 cited by 477

  24. BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF -Mutant Thyroid Cancer

    Authors: Gerald S. Falchook, Michael Millward, David S. Hong, Aung Naing, Sarina A. Piha‐Paul, Steven G. Waguespack, Maria E. Cabanillas, Steven I. Sherman, Bo Ma, Martin Curtis, Vicki Goodman, Razelle Kurzrock - Thyroid 2014 cited by 229